Number needed to treat (NNT) and cost of preventing an event (COPE) of PD-1/PD-L1 antibodies for previously treated advanced non-small cell lung cancer (NSCLC) patients in Brazil.

Oliveira, Fernanda; Lima, Joao PsDN

doi:10.1200/jco.2018.36.15_suppl.e18899

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The NNT to prevent one death (OS) or to prevent death or disease progression (PFS) at 12 months was calculated as shown in the Equation ( 1) 21 . Considering that COPE is the product of NNT and treatment cost, COPE estimates were calculated as described in Equation (2) 35,36 .…”

Section: Nnt and Cope Analysismentioning

confidence: 99%

Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective

Engel

Abadi

Haas

et al. 2021

Journal of Medical Economics

View full text Add to dashboard Cite

Background: Considering clinical benefits of new combination therapies for metastatic renal-cell carcinoma (mRCC), this study aims to calculate the number needed to treat (NTT) and the cost of preventing an event (COPE) for pembrolizumab plus axitinib (P þ A), and nivolumab plus ipilimumab (N þ I) as first-line treatments, from the Brazilian private perspective. Methods: Overall survival (OS) and progression-free survival (PFS) data for intermediate-and poor-risk groups were obtained from KEYNOTE-426 and CHECKMATE-214 trials for P þ A and N þ I, respectively, versus sunitinib as mRCC first-line treatment. Results: Considering a 12-month time horizon, 6 patients should be treated with P þ A to prevent one death with sunitinib use, resulting in a COPE of 3,773,865 BRL. Using N þ I, NNT for 12-month OS rate was 13 compared to sunitinib, with a COPE of 6,357,965 BRL. Regarding PFS data, NNT was also 6 when comparing P þ A versus sunitinib, with an estimated COPE of 3,773,865 BRL. Estimated NNT was 20 comparing N þ I and sunitinib, resulting in a COPE of 10,172,744 BRL. Cost differences between two treatment options, reached more than 6 million BRL for PFS, and 2 million BRL for OS. Conclusion: At the 12-month landmark, P þ A suggests better economic scenario versus N þ I as firstline mRCC treatment option for intermediate-and poor-risk groups, through an indirect comparison using sunitinib as a common comparator.

show abstract

Section: Nnt and Cope Analysismentioning

confidence: 99%

Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective

Engel

Abadi

Haas

et al. 2021

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

“…Regarding the Brazilian SSS perspective, Oliveira et al (2018) assessed the NNT for anti-PD-L1/anti-PD-1 agents available for NSCLC second-line treatment and reported measures ranging from 5 (nivolumab in patients with non-squamous disease and PD-L1 ≥ 1%) to 12.5 (atezolizumab in patients with PD-L1 ≥ 1%) with the use of immunotherapy post-platinum failure in a 24 months follow-up [40].…”

Section: Characterizing Uncertaintymentioning

confidence: 99%

Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer

Paladini

Veiga

Cerqueira

et al. 2021

Journal of Medical Economics

View full text Add to dashboard Cite

Declaration of financial/other relationshipsCRPdV, EC and MDA are employees of MSD Brazil, São Paulo, Brazil. LCH was an employee of MSD Brazil, São Paulo, Brazil, at the time this research was conducted. LP and CSB received honoraria from MSD Brazil to provide scientific consultancy for the study design and data analysis. Author ContributionsLP and CSB contributed to conception, design or planning of the study, analysis of the data, interpretation of the results, drafting the manuscript and critically reviewing or revising it for important intellectual content. MDA and EC contributed to conception, design or planning of the study, analysis of the data, interpretation of the results and critically reviewing or revising the manuscript for important intellectual content. CRPdV and LCH contributed to analysis and acquisition of the data, interpretation of the results, drafting the manuscript and critically reviewing or revising it for important intellectual content. JME peer reviewers on this manuscript have received an honorarium from JME for their review work, but have no other relevant financial relationships to disclose.

show abstract

Number needed to treat (NNT) and cost of preventing an event (COPE) of PD-1/PD-L1 antibodies for previously treated advanced non-small cell lung cancer (NSCLC) patients in Brazil.

Cited by 2 publications

References 0 publications

Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective

Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective

Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer

Contact Info

Product

Resources

About